Evidence map›Paper›PMID 41792123›Full record

ArticleJournal of feline medicine and surgery2026

Efficacy of high-dose carvedilol treatment for cats with stage B1 obstructive hypertrophic cardiomyopathy.

Shuji Satomi, Ryohei Suzuki, Yunosuke Yuchi, Haruka Kanno, Maria Inoue, Takahiro Teshima, Hirotaka Matsumoto

Abstract read
In one paragraph

Article in Journal of feline medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shuji SatomiLaboratory of Veterinary Internal Medicine, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.
Ryohei SuzukiLaboratory of Veterinary Internal Medicine, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.ORCID 0000-0001-9451-5854
Yunosuke YuchiLaboratory of Veterinary Internal Medicine, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.ORCID 0000-0002-6293-7320
Haruka KannoLaboratory of Veterinary Internal Medicine, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.
Maria InoueLaboratory of Veterinary Internal Medicine, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.
Takahiro TeshimaLaboratory of Veterinary Internal Medicine, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.
Hirotaka MatsumotoLaboratory of Veterinary Internal Medicine, Department of Veterinary Science, Faculty of Veterinary Medicine, Nippon Veterinary and Life Science University, Musashino-shi, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

ObjectivesThe aim of the study was to investigate the effects of high-dose (HD) carvedilol treatment in client-owned cats with stage B1 obstructive hypertrophic cardiomyopathy (oHCM) where a standard dose (SD) had failed to adequately alleviate left ventricular outflow tract (LVOT) obstruction.MethodsA prospective, interventional study was conducted in which cats underwent echocardiography, including evaluation of myocardial strain using speckle-tracking echocardiography. Myocardial injury was quantified using a cardiac troponin I (cTnI) assay. Echocardiographic variables and the cTnI level were compared before treatment and after SD and HD carvedilol treatment.ResultsLVOT velocity (LVOTV) decreased after SD compared with before treatment in all cats, but remained above 2.5 m/s after SD (before treatment 4.9 m/s [interquartile range [IQR] 4.3-5.0]; SD 4.3 m/s [IQR 3.9-4.7]), whereas HD decreased LVOTV to below 2.5 m/s in 10/11 cats (1.6 m/s [IQR 1.5-2.0]). Longitudinal strain was improved after SD and HD compared with before treatment (endocardial layer: before treatment 12.1% [IQR 9.6-15.8]; SD 20.0% [IQR 15.9-21.7]; HD 18.9% [IQR 12.9-22.8];

Indexed as

Cardiomyopathy, HypertrophicCarvedilolCat DiseasesAnimalsCatsEchocardiographyFemaleMaleProspective StudiesTreatment OutcomeTroponin ICarvedilolTroponin ICardiac biomarkerechocardiographyheart diseasemyocardial functionspeckle trackingstraintroponin

Identifiers

PMID41792123
PMCPMC13077148

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.